Figure 2
From: Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
Kaplan–Meier survival curves for PFS (left) and OS (right) depending on pathway alteration at next-generation sequencing analysis combined with EGFRvIII status.
